Science for a Healthier Tomorrow
Does Whole-Grain Processing Matter?

In a 12-week trial of 160 adults with type 2 diabetes, minimally processed whole grains lowered HbA1c about 0.2 percentage points more than milled ones.
Science for a Healthier Tomorrow
Science for a Healthier Tomorrow

In a 12-week trial of 160 adults with type 2 diabetes, minimally processed whole grains lowered HbA1c about 0.2 percentage points more than milled ones.

A 101,243-patient cohort links brown fat to lower odds of diabetes, and losartan to brown fat — but the metabolism claim comes from mice, not people.

In an open-label 26-week trial, adults with type 2 diabetes not on insulin lowered HbA1c 0.9 percentage points more with a CGM; the device maker paid.

A 44-study meta-analysis finds poor metabolic health predicts heart risk at least as strongly as weight category — but with caveats about pooled data.

A 786,557-person analysis finds a new clinical obesity definition counts more older adults than BMI but fewer young children; the authors call it preliminary.

Semaglutide extended median lifespan in female mice, but the human anti-aging case rests on a company preprint and unpublished biomarker data.

In a prespecified S-LiTE analysis, one year of exercise — not liraglutide alone — tracked with thinner carotid artery walls in 130 adults with obesity.

In old mice a low-protein diet with added methionine cut fat and frailty without cutting calories but did not extend life; a human diabetes link was unadjusted.

In an 810-person phase 3 trial in China, an investigational oral GLP-1 pill lowered HbA1c about as much as the diabetes pill dapagliflozin over 32 weeks.

A small crossover matched two meals on calories and nutrients. Insulin, energy use and fuel choice still differed — an acute lab signal, not weight or disease.